Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles

Dina Aggad; Chiara Mauriello Jimenez; Soraya Dib; Jonas G. Croissant; Laure Lichon; Danielle Laurencin; Sebastien Richeter; Marie Maynadier; Shahad K. Alsaiari; Makhlouf Boufatit; Laurence Raehm; Marcel Garcia; Niveen M. Khashab; Magali Gary-Bobo; Jean-Olivier Durand

doi:10.1002/cnma.201700264

Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles

Dina Aggad, Chiara Mauriello Jimenez, Soraya Dib, Jonas G. Croissant, Laure Lichon, Danielle Laurencin, Sebastien Richeter, Marie Maynadier, Shahad K. Alsaiari, Makhlouf Boufatit, Laurence Raehm, Marcel Garcia, Niveen M. Khashab, Magali Gary-Bobo^*, Jean-Olivier Durand

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Gemcitabine hydrochloride is an FDA-approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half-life of 8-17min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene-based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two-photon photodynamic therapy. Two-photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.

Original language	English
Pages (from-to)	46-51
Number of pages	6
Journal	ChemNanoMat
Volume	4
Issue number	1
DOIs	https://doi.org/10.1002/cnma.201700264
State	Published - Jan 2018

Keywords

gemcitabine
mesoporous organosilica nanoparticles
photodynamic therapy
porphyrin
two-photon
HUMAN PANCREATIC-CANCER
SILICA NANOPARTICLES
DRUG-DELIVERY
IN-VITRO
NANORODS
NANOSPHERES
ENHANCEMENT
RESISTANCE
CHEMISTRY
EMISSION

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cnma.201700264

Cite this

Aggad, D., Jimenez, C. M., Dib, S., Croissant, J. G., Lichon, L., Laurencin, D., Richeter, S., Maynadier, M., Alsaiari, S. K., Boufatit, M., Raehm, L., Garcia, M., Khashab, N. M., Gary-Bobo, M., & Durand, J.-O. (2018). Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles. ChemNanoMat, 4(1), 46-51. https://doi.org/10.1002/cnma.201700264

@article{605281a3ee264657b1fbbb9a08e7233c,

title = "Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles",

abstract = "Gemcitabine hydrochloride is an FDA-approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half-life of 8-17min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene-based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two-photon photodynamic therapy. Two-photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.",

keywords = "gemcitabine, mesoporous organosilica nanoparticles, photodynamic therapy, porphyrin, two-photon, HUMAN PANCREATIC-CANCER, SILICA NANOPARTICLES, DRUG-DELIVERY, IN-VITRO, NANORODS, NANOSPHERES, ENHANCEMENT, RESISTANCE, CHEMISTRY, EMISSION",

author = "Dina Aggad and Jimenez, {Chiara Mauriello} and Soraya Dib and Croissant, {Jonas G.} and Laure Lichon and Danielle Laurencin and Sebastien Richeter and Marie Maynadier and Alsaiari, {Shahad K.} and Makhlouf Boufatit and Laurence Raehm and Marcel Garcia and Khashab, {Niveen M.} and Magali Gary-Bobo and Jean-Olivier Durand",

year = "2018",

month = jan,

doi = "10.1002/cnma.201700264",

language = "English",

volume = "4",

pages = "46--51",

journal = "ChemNanoMat",

issn = "2199-692X",

publisher = "Wiley-VCH Verlag",

number = "1",

}

Aggad, D, Jimenez, CM, Dib, S, Croissant, JG, Lichon, L, Laurencin, D, Richeter, S, Maynadier, M, Alsaiari, SK, Boufatit, M, Raehm, L, Garcia, M, Khashab, NM, Gary-Bobo, M & Durand, J-O 2018, 'Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles', ChemNanoMat, vol. 4, no. 1, pp. 46-51. https://doi.org/10.1002/cnma.201700264

TY - JOUR

T1 - Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles

AU - Aggad, Dina

AU - Jimenez, Chiara Mauriello

AU - Dib, Soraya

AU - Croissant, Jonas G.

AU - Lichon, Laure

AU - Laurencin, Danielle

AU - Richeter, Sebastien

AU - Maynadier, Marie

AU - Alsaiari, Shahad K.

AU - Boufatit, Makhlouf

AU - Raehm, Laurence

AU - Garcia, Marcel

AU - Khashab, Niveen M.

AU - Gary-Bobo, Magali

AU - Durand, Jean-Olivier

PY - 2018/1

Y1 - 2018/1

N2 - Gemcitabine hydrochloride is an FDA-approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half-life of 8-17min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene-based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two-photon photodynamic therapy. Two-photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.

AB - Gemcitabine hydrochloride is an FDA-approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half-life of 8-17min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene-based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two-photon photodynamic therapy. Two-photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.

KW - gemcitabine

KW - mesoporous organosilica nanoparticles

KW - photodynamic therapy

KW - porphyrin

KW - two-photon

KW - HUMAN PANCREATIC-CANCER

KW - SILICA NANOPARTICLES

KW - DRUG-DELIVERY

KW - IN-VITRO

KW - NANORODS

KW - NANOSPHERES

KW - ENHANCEMENT

KW - RESISTANCE

KW - CHEMISTRY

KW - EMISSION

U2 - 10.1002/cnma.201700264

DO - 10.1002/cnma.201700264

M3 - Article

SN - 2199-692X

VL - 4

SP - 46

EP - 51

JO - ChemNanoMat

JF - ChemNanoMat

IS - 1

ER -

Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this